Download MendeleyRational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties.
Xiao, P., Duan, Z., Liu, Z., Chen, L., Zhang, D., Liu, L., Zhou, C., Gan, J., Dong, Z., Yang, C.G.(2023) J Med Chem 66: 9731-9752
- PubMed: 37418628
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00543
- Primary Citation of Related Structures:
8IT9 - PubMed Abstract:
The fat mass and obesity-associated protein (FTO) is an RNA N 6 -methyladenosine (m 6 A) demethylase highly expressed in diverse cancers including acute myeloid leukemia (AML). To improve antileukemia drug-like properties, we have designed 44 /ZLD115, a flexible alkaline side-chain-substituted benzoic acid FTO inhibitor derived from FB23. A combination of structure-activity relationship analysis and lipophilic efficiency-guided optimization demonstrates that 44 /ZLD115 exhibits better drug-likeness than the previously reported FTO inhibitors, FB23 and 13a /Dac85. Then, 44 /ZLD115 shows significant antiproliferative activity in leukemic NB4 and MOLM13 cell lines. Moreover, 44 /ZLD115 treatment noticeably increases m 6 A abundance on the AML cell RNA, upregulates RARA gene expression, and downregulates MYC gene expression in MOLM13 cells, which are consistent with FTO gene knockdown. Lastly, 44 /ZLD115 exhibits antileukemic activity in xenograft mice without substantial side effects. This FTO inhibitor demonstrates promising properties that can be further developed for antileukemia applications.
Organizational Affiliation:
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
